Jun 23, 2020 Effects on Pruritus and Sleep Disturbance in Patients with Primary Biliary Cholangitis (PBC) after 1 Year of Treatment with Seladelpar, a Peroxisome Proliferator-Activated Receptor Delta Agonist: Results of an Open-label Phase 2 Study
Nov 11, 2019 Structural and Biophysical Characterization of the Origins of the PPAR Selectivity of Seladelpar and Elafibranor, Peroxisomal Proliferator Activated Receptor (PPAR) Agonists Targeting Inflammatory Liver Diseases
Nov 9, 2019 Pharmacokinetics of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) with or without Cirrhosis
May 20, 2019 Capturing the Experience and Impact of Itch in Patients with Primary Biliary Cholangitis
May 20, 2019 Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects with Hepatic Impairment
May 20, 2019 Seladelpar for the Treatment of Primary Biliary Cholangitis, Experience with 25 Cirrhotic Patients
Apr 12, 2019 EASL 2019 Pharmacokinetics Safety and Tolerability of Seladelpar in Subjects with Hepatic Impairment
Apr 12, 2019 Comparison of Seladelpar and Combinations with Liraglutide or Selonsertib for Improvement of Fibrosis and NASH in a Diet-Induced and Biopsy-Confirmed Mouse Model of NASH
Apr 12, 2019 Treatment of Patients with Primary Biliary Cholangitis with Seladelpar for 52 Weeks Improves Predicted Transplant-free Survival
